$48.65
-0.48 (-0.98%)
Performance
1D
—
1W
—
1M
—
3M
-46.88%
6M
-2.43%
1Y
+55.93%
YTD
-45.26%
Open$47.78
Previous Close$49.13
Day High$49.33
Day Low$46.85
52W High$118.84
52W Low$20.44
Volume—
Avg Volume844.9K
Market Cap3.96B
P/E Ratio—
EPS$-11.63
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$97.75
Below
SMA 200
$64.49
Below
RSI (14)
50.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Buy
12 analysts
Price Target
-31.0% upside
Current
$48.65
$48.65
Target
$33.59
$33.59
$28.45
$33.59 avg
$56.21
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 279.70M | 2.03B | 2.02B |
| Net Income | -4,514,140,048 | 163.05M | 154.03M |
| Profit Margin | -1,613.9% | 8.0% | 7.6% |
| EBITDA | -4,576,935,899 | 233.27M | 214.07M |
| Free Cash Flow | — | 175.18M | 137.52M |
| Rev Growth | +104.8% | +17.3% | +15.5% |
| Debt/Equity | — | 0.84 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $205.20 | +0.13% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $348.43 | -0.38% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.11 | +0.56% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $448.62 | -0.58% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $741.69 | +0.70% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $308.05 | +0.45% | 139.7 | 43.84B |